Protagonist Therapeutics Company Profile (NASDAQ:PTGX)

About Protagonist Therapeutics (NASDAQ:PTGX)

Protagonist Therapeutics logoProtagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn's disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PTGX
  • CUSIP: N/A
  • Web: www.protagonist-inc.com
Capitalization:
  • Market Cap: $284.8 million
  • Outstanding Shares: 16,902,000
Average Prices:
  • 50 Day Moving Avg: $13.69
  • 200 Day Moving Avg: $12.13
  • 52 Week Range: $8.00 - $26.36
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.46
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $3.61 per share
  • Price / Book: 4.67
Profitability:
  • EBIDTA: ($47,600,000.00)
  • Return on Equity: -59.45%
  • Return on Assets: -54.53%
Debt:
  • Current Ratio: 7.38%
  • Quick Ratio: 7.38%
Misc:
  • Average Volume: 76,142 shs.
  • Short Ratio: 9.47
 

Frequently Asked Questions for Protagonist Therapeutics (NASDAQ:PTGX)

What is Protagonist Therapeutics' stock symbol?

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.89) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.70. View Protagonist Therapeutics' Earnings History.

When will Protagonist Therapeutics make its next earnings announcement?

Protagonist Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for Protagonist Therapeutics.

Where is Protagonist Therapeutics' stock going? Where will Protagonist Therapeutics' stock price be in 2017?

2 brokers have issued 12 month target prices for Protagonist Therapeutics' shares. Their forecasts range from $36.00 to $45.00. On average, they expect Protagonist Therapeutics' share price to reach $40.50 in the next twelve months. View Analyst Ratings for Protagonist Therapeutics.

Who are some of Protagonist Therapeutics' key competitors?

Who are Protagonist Therapeutics' key executives?

Protagonist Therapeutics' management team includes the folowing people:

  • Harold E. Selick Ph.D., Independent Chairman of the Board
  • Dinesh V. Patel Ph.D., President, Chief Executive Officer, Director
  • Thomas P. O'Neil, Chief Financial Officer
  • William A. Hodder, Senior Vice President - Corporate Development
  • David Y. Liu Ph.D., Chief Scientific Officer, Head of Research & Development
  • Ashok Bhandari Ph.D., Vice President - Chemistry
  • Larry Mattheakis Ph.D., Vice President - Biology
  • Mark Smythe Ph.D., Vice President -Technology & Alliances
  • Thamil Annamalai, Senior Director - Pre-clinical Development
  • Richard S. Shames M.D., Chief Medical Officer

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an initial public offering on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.

Who owns Protagonist Therapeutics stock?

Protagonist Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Pharmstandard International S.A. (5.81%), Vanguard Group Inc. (1.93%), Senzar Asset Management LLC (1.62%), State Street Corp (0.67%) and Northern Trust Corp (0.59%). Company insiders that own Protagonist Therapeutics stock include Armen Shanafelt, David Y Liu and Richard S Shames. View Institutional Ownership Trends for Protagonist Therapeutics.

Who sold Protagonist Therapeutics stock? Who is selling Protagonist Therapeutics stock?

Protagonist Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including PDT Partners LLC. Company insiders that have sold Protagonist Therapeutics stock in the last year include David Y Liu and Richard S Shames. View Insider Buying and Selling for Protagonist Therapeutics.

Who bought Protagonist Therapeutics stock? Who is buying Protagonist Therapeutics stock?

Protagonist Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, State Street Corp, Northern Trust Corp, Northern Capital Management LLC, Vanguard Group Inc., FMR LLC, Rhumbline Advisers and Teachers Advisors LLC. View Insider Buying and Selling for Protagonist Therapeutics.

How do I buy Protagonist Therapeutics stock?

Shares of Protagonist Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Protagonist Therapeutics' stock price today?

One share of Protagonist Therapeutics stock can currently be purchased for approximately $16.85.


MarketBeat Community Rating for Protagonist Therapeutics (NASDAQ PTGX)
Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  54 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  132
MarketBeat's community ratings are surveys of what our community members think about Protagonist Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Protagonist Therapeutics (NASDAQ:PTGX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $40.50 (140.36% upside)

Analysts' Ratings History for Protagonist Therapeutics (NASDAQ:PTGX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/21/2017BTIG ResearchInitiated CoverageBuy -> Buy$36.00MediumView Rating Details
5/31/2017BMO Capital MarketsBoost Price TargetOutperform$34.00 -> $45.00HighView Rating Details
9/6/2016Leerink SwannInitiated CoverageOutperform$17.00N/AView Rating Details
9/6/2016Barclays PLCInitiated CoverageOverweight$18.00N/AView Rating Details
(Data available from 9/24/2015 forward)

Earnings

Earnings History for Protagonist Therapeutics (NASDAQ:PTGX)
Earnings by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)
Earnings History by Quarter for Protagonist Therapeutics (NASDAQ PTGX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017N/AView Earnings Details
8/8/2017Q2 2017($0.19)($0.89)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.61)($0.84)ViewN/AView Earnings Details
3/7/2017Q4 2016($0.49)($0.67)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.58)($0.87)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Protagonist Therapeutics (NASDAQ:PTGX)
2017 EPS Consensus Estimate: ($3.50)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.64)($0.64)($0.64)
Q2 20171($0.92)($0.92)($0.92)
Q3 20171($0.95)($0.95)($0.95)
Q4 20171($0.99)($0.99)($0.99)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Protagonist Therapeutics (NASDAQ:PTGX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Protagonist Therapeutics (NASDAQ:PTGX)
Institutional Ownership Percentage: 48.04%
Insider Trades by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)
Institutional Ownership by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)
Insider Trades by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/12/2017Richard S. ShamesInsiderSell3,687$14.31$52,760.97View SEC Filing  
8/29/2017Richard S. ShamesInsiderSell1,512$17.00$25,704.00View SEC Filing  
8/28/2017David Y LiuInsiderSell3,500$15.00$52,500.00View SEC Filing  
7/10/2017David Y. LiuInsiderSell3,500$12.68$44,380.00View SEC Filing  
8/16/2016Armen ShanafeltDirectorBuy583,333$12.00$6,999,996.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Protagonist Therapeutics (NASDAQ:PTGX)
Latest Headlines for Protagonist Therapeutics (NASDAQ:PTGX)
Source:
DateHeadline
finance.yahoo.com logoProtagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300
finance.yahoo.com - September 22 at 2:39 PM
americanbankingnews.com logoAnalysts Issue Forecasts for Protagonist Therapeutics, Inc.'s FY2019 Earnings (PTGX)
www.americanbankingnews.com - September 22 at 12:52 PM
finance.yahoo.com logo/C O R R E C T I O N -- Protagonist Therapeutics, Inc./
finance.yahoo.com - September 15 at 7:51 AM
americanbankingnews.com logoProtagonist Therapeutics, Inc. (PTGX) Insider Richard S. Shames Sells 3,687 Shares
www.americanbankingnews.com - September 12 at 10:16 PM
finance.yahoo.com logoProtagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 12 at 8:50 AM
americanbankingnews.com logoProtagonist Therapeutics, Inc. (PTGX) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - September 11 at 10:18 PM
americanbankingnews.com logoProtagonist Therapeutics (PTGX) and Jaguar Animal Health (JAGX) Critical Comparison
www.americanbankingnews.com - September 1 at 6:06 AM
americanbankingnews.com logoInsider Selling: Protagonist Therapeutics, Inc. (PTGX) Insider Sells 1,512 Shares of Stock
www.americanbankingnews.com - August 30 at 8:50 PM
americanbankingnews.com logoProtagonist Therapeutics, Inc. (PTGX) Insider David Y. Liu Sells 3,500 Shares
www.americanbankingnews.com - August 29 at 10:34 PM
americanbankingnews.com logoProtagonist Therapeutics, Inc. (PTGX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - August 29 at 12:40 AM
americanbankingnews.com logoProtagonist Therapeutics, Inc. (PTGX) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - August 28 at 11:14 PM
streetinsider.com logoProtagonist Therapeutics (PTGX) Announces Closing of Janssen Pact for PTG-200 and Receipt of $50M Payment
www.streetinsider.com - August 25 at 10:23 AM
finance.yahoo.com logoProtagonist Therapeutics Announces Closing of Janssen License and Collaboration Agreement for PTG-200 and Receipt of $50 Million Payment
finance.yahoo.com - August 25 at 10:23 AM
americanbankingnews.com logoZacks: Brokerages Set $29.67 Price Target for Protagonist Therapeutics, Inc. (PTGX)
www.americanbankingnews.com - August 25 at 2:26 AM
americanbankingnews.com logoZacks: Brokerages Set $29.67 Target Price for Protagonist Therapeutics, Inc. (PTGX)
www.americanbankingnews.com - August 21 at 8:08 PM
americanbankingnews.com logoProtagonist Therapeutics, Inc. (PTGX) Expected to Post Earnings of -$0.95 Per Share
www.americanbankingnews.com - August 18 at 6:12 PM
americanbankingnews.com logoZacks Investment Research Upgrades Protagonist Therapeutics, Inc. (PTGX) to Buy
www.americanbankingnews.com - August 18 at 6:56 AM
americanbankingnews.com logoLeerink Swann Research Analysts Raise Earnings Estimates for Protagonist Therapeutics, Inc. (PTGX)
www.americanbankingnews.com - August 17 at 8:04 AM
americanbankingnews.com logoZacks: Protagonist Therapeutics, Inc. (PTGX) Given $29.67 Average Price Target by Brokerages
www.americanbankingnews.com - August 14 at 6:16 AM
americanbankingnews.com logoProtagonist Therapeutics, Inc. (PTGX) Issues Quarterly Earnings Results, Misses Estimates By $0.70 EPS
www.americanbankingnews.com - August 9 at 4:46 PM
finance.yahoo.com logoProtagonist Therapeutics Reports Second Quarter 2017 Financial Results and Business Highlights
finance.yahoo.com - August 9 at 6:40 AM
americanbankingnews.com logoBrokerages Expect Protagonist Therapeutics, Inc. (PTGX) to Announce ($0.92) Earnings Per Share
www.americanbankingnews.com - July 30 at 10:04 PM
americanbankingnews.com logoProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Coverage Initiated by Analysts at BTIG Research
www.americanbankingnews.com - July 22 at 7:03 PM
americanbankingnews.com logoDavid Y. Liu Sells 3,500 Shares of Protagonist Therapeutics, Inc. (PTGX) Stock
www.americanbankingnews.com - July 12 at 8:42 PM
americanbankingnews.com logoBrokerages Expect Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to Announce ($0.92) EPS
www.americanbankingnews.com - July 12 at 4:18 PM
americanbankingnews.com logo-$0.92 Earnings Per Share Expected for Protagonist Therapeutics, Inc. (NASDAQ:PTGX) This Quarter
www.americanbankingnews.com - July 7 at 10:53 AM
americanbankingnews.com logo Protagonist Therapeutics, Inc. (PTGX) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - June 21 at 7:50 AM
americanbankingnews.com logoProtagonist Therapeutics, Inc. (PTGX) Expected to Announce Earnings of -$0.92 Per Share
www.americanbankingnews.com - June 13 at 10:20 AM
americanbankingnews.com logoProtagonist Therapeutics, Inc. (PTGX) Sees Large Increase in Short Interest
www.americanbankingnews.com - June 12 at 7:12 AM
finance.yahoo.com logoProtagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its Board of Directors
finance.yahoo.com - June 8 at 8:59 AM
finance.yahoo.com logoA small biotech wants to disrupt billion-dollar injectable drug markets with a single pill
finance.yahoo.com - June 7 at 7:18 PM
americanbankingnews.com logoFY2018 EPS Estimates for Protagonist Therapeutics Inc (PTGX) Decreased by Analyst
www.americanbankingnews.com - June 5 at 7:37 AM
rttnews.com logoProtagonist Therapeutics Inc. (PTGX) Jumped On Janssen Biotech Deal
www.rttnews.com - May 31 at 1:01 PM
finance.yahoo.com logoWhy Analysts Think Protagonist Therapeutics Could Still More Than Double After the News
finance.yahoo.com - May 31 at 1:01 PM
americanbankingnews.com logoProtagonist Therapeutics Inc (PTGX) Stock Rating Reaffirmed by BMO Capital Markets
www.americanbankingnews.com - May 31 at 8:40 AM
247wallst.com logoCan Protagonist Therapeutics Stock Still Double After Its Huge Gain?
247wallst.com - May 30 at 7:03 PM
nasdaq.com logoProtagonist Therapeutics Inc. (PTGX) Is Up Sharply On Collaboration Agreement
www.nasdaq.com - May 30 at 7:03 PM
finance.yahoo.com logoProtagonist Therapeutics Inks License Pact With Johnson & Johnson's Janssen
finance.yahoo.com - May 30 at 7:03 PM
feeds.benzinga.com logoProtagonist Therapeutics Spikes Sharply After Agreement With Janssen
feeds.benzinga.com - May 30 at 11:43 AM
finance.yahoo.com logoProtagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease
finance.yahoo.com - May 30 at 9:43 AM
finance.yahoo.com logoWhy Protagonist Therapeutics Shares Are Climbing
finance.yahoo.com - May 30 at 9:43 AM
americanbankingnews.com logoZacks: Protagonist Therapeutics Inc (PTGX) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - May 29 at 12:30 PM
finance.yahoo.com logoProtagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300
finance.yahoo.com - May 26 at 6:12 AM
streetinsider.com logoProtagonist Therapeutics (PTGX) Awarded $1.34M in SBIR Funding for Development of Biomarkers of IL-23 Receptor Antagonist
www.streetinsider.com - May 25 at 12:40 AM
finance.yahoo.com logoProtagonist Therapeutics Receives $1.34 Million SBIR Funding for Development of Biomarkers of IL-23 Receptor Antagonist Activity
finance.yahoo.com - May 24 at 9:57 AM
americanbankingnews.com logoLeerink Swann Brokers Lower Earnings Estimates for Protagonist Therapeutics Inc (PTGX)
www.americanbankingnews.com - May 17 at 7:46 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Protagonist Therapeutics Inc (PTGX) Will Announce Earnings of -$0.66 Per Share
www.americanbankingnews.com - May 16 at 6:24 PM
americanbankingnews.com logoProtagonist Therapeutics Inc (PTGX) Issues Earnings Results
www.americanbankingnews.com - May 11 at 6:14 PM
finance.yahoo.com logoProtagonist Therapeutics Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 7:34 PM
finance.yahoo.com logoProtagonist Therapeutics posts 1Q loss
finance.yahoo.com - May 10 at 7:34 PM

Social

Chart

Protagonist Therapeutics (PTGX) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff